Coverage & scale too big ? - Coverage & scale is getting bigger every day, COVID is increasing the addressable market considerably for OSP, via permanent kidney & heart damage.
Also indications in the previous & current presentation that Dyvert could/will be used for other imaging procedures, extremities, diabetes etc, so expanding market/use
The company 'just' has to rain in costs & it will do well long term
https://www.hopkihttps://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-kidney-damage-caused-by-covid19#:~:text=COVID%2D19%20Kidney%20Damage%3A%20A%20Possible%20Complication&text=Reports%20from%20doctors%20in%20New,severe%20enough%20to%20require%20dialysis.nsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-kidney-damage-caused-by-covid19#:~:text=COVID%2D19%20Kidney%20Damage%3A%20A%20Possible%20Complication&text=Reports%20from%20doctors%20in%20New,severe%20enough%20to%20require%20dialysis.
- Forums
- ASX - By Stock
- OSP
- Ann: Osprey CEO Investor Presentation
Ann: Osprey CEO Investor Presentation, page-7
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)